VHT vs XLV: Which Healthcare ETF Wins?
💡 Key Takeaway
VHT's broader diversification and superior long-term returns make it the better choice for most investors, despite XLV's slightly lower fee.
What Happened: A Tale of Two Healthcare ETFs
The article compares two popular healthcare ETFs: the Vanguard Health Care ETF (VHT) and the State Street Health Care Select Sector SPDR ETF (XLV). Both funds offer exposure to the healthcare sector, but they differ significantly in their composition and investment strategy.
VHT tracks a broad index of 423 medical companies, including small- and mid-cap stocks, while XLV focuses strictly on the 60 healthcare names within the S&P 500, making it a large-cap-heavy fund. This difference in breadth is a key factor in their performance and risk profiles.
As of August 6, 2026, VHT's share price was $309.02, while XLV traded at $164.45. Both funds have similar expense ratios (0.08% for XLV, 0.09% for VHT) and identical dividend yields of 1.5%.
Over the past year, VHT returned 30.1% versus XLV's 28.2%, and VHT also outperformed on 3-year and 10-year annualized returns (8.9% vs 8.4% and 9.9% vs 9.8%, respectively). XLV only beat VHT on the 5-year annualized return (5.9% vs 5.1%).
The article concludes that VHT is the better buy for long-term investors due to its broader diversification and superior performance across most time frames, despite XLV's slightly lower cost.
Why It Matters: Diversification vs. Concentration
This comparison matters because healthcare is a cornerstone of the U.S. economy, and many investors use ETFs to gain exposure to this sector. The choice between VHT and XLV can significantly impact portfolio risk and returns.
XLV's concentration in large-cap stocks means it's more susceptible to the performance of a few mega-cap companies like Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). In contrast, VHT's inclusion of small- and mid-cap stocks provides broader diversification, which can reduce volatility and capture growth from smaller companies.
For investors, this means VHT may offer a smoother ride during market downturns, as its broader holdings can cushion the impact of a single stock's poor performance. On the other hand, XLV's concentration could lead to higher returns if large-caps outperform, but it also carries more risk.
The performance data shows that VHT has historically delivered better returns over most periods, suggesting that its diversification has paid off. This is particularly relevant for long-term investors who are looking to build wealth steadily over time.
Ultimately, the choice between these two ETFs depends on an investor's risk tolerance and investment goals. Those seeking broad exposure with potentially lower risk may prefer VHT, while those comfortable with concentration risk might opt for XLV.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
VHT is the better buy for long-term investors seeking diversified healthcare exposure.
VHT's broader portfolio of 423 holdings, including small- and mid-caps, reduces concentration risk and has historically delivered superior returns over 1, 3, and 10-year periods. While XLV has a slightly lower expense ratio, the performance advantage and diversification benefits of VHT outweigh the minimal cost difference.
What This Means for Me
